Lonza's GS Gene Expression System® is widely used for the expression and manufacturing of biologics. The latest addition to the GS® toolbox, GS Effex® is a FUT8 knockout cell line derived from the industry-known GS Xceed® CHOK1SV GS-KO®. GS Effex® produces antibodies free of fucose.

This lack of fucose enhances antibody-dependent cellular cytotoxicity (ADCC), increasing the potency of antibody immunotherapies.

You may also be interested in:
Out-Licensed Expression Technologies
Enhanced ADCC
Monoclonal Antibody
GS Gene Expression System®
GS piggyBac® Transposon System
GS Xceed® Gene Expression System
GSquad® Vectors
Mammalian Expression Technologies
GS Effex®
By clicking "Access Content" you agree to our Legal Disclaimer and the Lonza Privacy and Cookies Policy.

Latest content
Latest briefing from the Knowledge Center
Webinar (on-demand)
Charting a Successful CMC Journey for Your ADC Drug Product
Bioconjugates and Antibody drug conjugates (ADCs) are revolutionizing cancer therapy with their...
ADC vial with gradient background - close crop
Interview
Expert Q&A: Accelerate Your ADC Journey
Filling the Need for Integrated Bioconjugate Solutions Antibody drug conjugates (ADCs) are...
KC Video thumbnail
Video
mRNA and LNP Encapsulation Capabilities at our Geleen/NL Center of Excellence
Discover how our team, with its impressive mRNA/LNP track record, can help you progress your...
Mammalian Biologics Drug Substance Manufacture MC1
Article
How Emerging Biotechs can Benefit by Partnering with a CDMO for Early Stage Development
The partnership between CDMOs and emerging biotech companies in early-stage development can be...
Webinar (on-demand)
Early Preclinical Development of mRNA/LNP Projects, Transitioning Successfully to cGMP...
View our on-demand webinar exploring the development steps that lead to an mRNA construct optimized...
Webinar (on-demand)
Enhanced GS® CHO Vector Technology for Improved Expression Control of Biotherapeutic Proteins
Many of today’s expression platforms for recombinant protein production have been optimised for the...
man working with microscope in lab,Process Development,Biologics_Slough_18,,lab in slough,tech working in lab with computer,male tech pipetting,tech holding vial,tech working,Cell Iine process development,biologics lab worker, ,Biologics_Slough_29,Biologics , Biologics Slough
Webinar (on-demand)
Integrating a High Sensitivity Immunopeptidomics (MAPPs) Assay in Preclinical Immunogenicity Risk...
Immunogenicity poses a critical risk to all biologics, including monoclonal antibodies, ADCs,...
Webinar (on-demand)
Navigating Biopharma Commercialization: The Interplay of Regulatory Affairs, Process Development and...
This on-demand webinar explores the essential alignment between regulatory affairs, process...
Biologics_Portsmouth_060
Article
Considerations for Successful Tech Transfer of a Biologics Upstream Process
In this European Pharmaceutical Review article, bioprocess experts from Lonza discuss how molecular...
e-book
Experts in Expression: Recent Advances in CHO Upstream Bioproduction
Constantly evolving biopharmaceutical pipelines require continuous evolution of CHO-based...
Article
Powering the Development of Tomorrow’s Bispecific Antibodies
bYlok® technology is changing the way bispecific antibodies are designed. Achieving the correct...
Webinar (on-demand)
Tech Transfer Strategies and Best Practices to Optimize Your Clinical and Commercial Supply
Tech Transfers for biological products, whether they occur from a pharma company, another CMO, or a...